Merck's Keytruda boosts response in hard-to-treat lung cancer

(Reuters) - The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.

An early look at results of a 204-patient trial showed an overall response rate of 58.4 percent for newly-diagnosed patients given Keytruda plus carboplatin and paclitaxel or Celgene Corp's Abraxane. That compared to 35 percent for chemotherapy alone.

The interim results will be discussed in greater detail next month at the annual meeting of the American Society of Clinical Oncology (ASCO), where data from several Keytruda trials and other therapies that help the immune system fight cancer will be presented. Data on a rival Roche drug from a similar squamous cell lung cancer trial will be featured at the meeting.

The duration of response was more than six months in 65.8 percent of patients given the Keytruda regimen compared with 45.6 percent of those who received chemotherapy alone, Merck said.

Serious side effects were seen in 64.4 percent of Keytruda patients and 74.5 percent of patients given just chemotherapy.

Keytruda is the only immunotherapy approved in the United States to treat lung cancer patients who have not received prior treatment. That approval is for non-squamous non-small cell lung cancer (NSCLC), the most common form of the disease.

Squamous cell, a type of NSCLC, accounts for about 30 percent of all lung cancers, according to the American Cancer Society. People diagnosed with squamous cell lung cancer typically have a poor prognosis since the disease is often first diagnosed after it has spread.

(Reporting By Deena Beasley; Editing by Bill Berkrot)

Related News

Philippine mining firms urge minister to publish...

Feb 7, 2017

US-PHILIPPINES-MINING:Philippine mining firms urge minister to publish audit

China, United States cannot afford conflict:...

Feb 7, 2017

US-AUSTRALIA-CHINA-TRUMP:China, United States cannot afford conflict: Chinese foreign minister

Bitcoin hits one-month high after China FX...

Feb 7, 2017

US-GLOBAL-MARKETS-BITCOIN:Bitcoin hits one-month high after China FX reserves fall

China 'mending its ways' on unethical organ...

Feb 8, 2017

US-VATICAN-TRANSPLANTS-CHINA:China 'mending its ways' on unethical organ transplants, official says

Tillerson stresses cooperation in calls with...

Feb 7, 2017

US-USA-ASIA-TILLERSON:Tillerson stresses cooperation in calls with Australia, Japan, South Korea

China says United States should 'brush up on'...

Feb 8, 2017

US-SOUTHCHINASEA-CHINA-USA:China says United States should 'brush up on' South China Sea history

About Us

In the busy city of New York, News On Express fills you in with all the breaking world news, in short, and brief news articles so that you can read them on-the-go.

Contact us: sales[at]newsonexpress.com

Subscribe Now!